十八烷过氧酸 | 5796-86-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 十八烷过氧酸
• 英文名称: peroxystearic acid
• 英文别名: Peroxystearinsaeure；hydroxyl stearate；hydroxy stearate；Octadecaneperoxoic acid
• CAS: 5796-86-1
• 化学式: C₁₈H₃₆O₃
• 分子量: 300.482
• InChiKey: SHBUUTHKGIVMJT-UHFFFAOYSA-N

物化性质

• 熔点：
  65-65.5 °C
• 沸点：
  399.8±25.0 °C(Predicted)
• 密度：
  0.919±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  21
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  硬脂酸	stearic acid	57-11-4	C18H36O2	284.483
  硬酯酸甲酯C18	Methyl stearate	112-61-8	C19H38O2	298.51

反应信息

• 作为产物：
  描述：

  硬酯酸甲酯C18 在 硫酸 、 双氧水 作用下， 生成 十八烷过氧酸
  参考文献：
  名称：

  Peroxides. II. Preparation, Characterization and Polarographic Behavior of Longchain Aliphatic Peracids²

  摘要：

  DOI：

  10.1021/ja01620a023

文献信息

• ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
  申请人：An2H Discovery Limited

  公开号：US20200172497A1

  公开（公告）日：2020-06-04

  The present disclosure is directed to asymmetric triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R 1 , R 2 , R 3 , M 1 , M 2 , M 3 , L 1 , L 2 , and L 3 are as defined herein.

  本公开涉及公式（I）和公式（II）的不对称三唑苯甲酰胺化合物，以及其制药组合物和调节或激活Parkin连接酶的方法。本公开还涉及治疗和/或减少与激活Parkin连接酶相关的疾病或症状的方法。R1、R2、R3、M1、M2、M3、L1、L2和L3如本文所定义。
• [EN] TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME<br/>[FR] DÉRIVÉS DE TRIAZOLE BENZAMIDE ET COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT ASSOCIÉS
  申请人：AN2H DISCOVERY LTD

  公开号：WO2017210694A1

  公开（公告）日：2017-12-07

  The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.

  本公开涉及式(I)和式(II)的三唑苯甲酰胺化合物，以及其药物组合物和调节或激活Parkin连接酶的方法。本公开还涉及治疗和/或减少与激活Parkin连接酶相关的疾病或症状的方法。R1、R2、R3、M1、M2、M3、L1、L2和L3如本文所定义。
• UVA irradiation of fatty acids and their oxidized products substantially increases their ability to generate singlet oxygen
  作者：Johannes Regensburger、Tim Maisch、Alena Knak、Anita Gollmer、Ariane Felgentraeger、Karin Lehner、Wolfgang Baeumler

  DOI：10.1039/c3cp51399h

  日期：——

  UVA radiation plays an important role for adverse reactions in human tissue. UVA penetrates epidermis and dermis of skin being absorbed by various biomolecules, especially endogenous photosensitizers. This may generate deleterious singlet oxygen (1O2) that oxidizes fatty acids in cell membranes, lipoproteins, and other lipid-containing structures such as the epidermal barrier. Indications exist that fatty acids are not only the target of 1O2 but also act as potential photosensitizers under UVA irradiation, if already oxidized. Five different fatty acids in ethanol solution (stearic, oleic, linoleic, linolenic and arachidonic acid) were exposed to UVA radiation (355 nm, 100 mW) for 30 seconds. 1O2 luminescence was detected time-resolved at 1270 nm and confirmed in spectrally-resolved experiments. The more double bonds fatty acids have the more 1O2 photons were detected. In addition, fatty acids were continuously exposed to broadband UVA for up to 240 min. During that time span, UVA absorption and 1O2 luminescence substantially increased with irradiation time, reached a maximum and decreased again. HPLC-MS analysis showed that the amount of peroxidized fatty acids and the 1O2 generation increased and decreased in parallel. This indicates the high potential of peroxidized fatty acids to produce 1O2 under UVA irradiation. In conclusion, fatty acids along with peroxidized products are weak endogenous photosensitizers but become strong photosensitizers under continuous UVA irradiation. Since fatty acids and their oxidized products are ubiquitous in living cells and in skin, which is frequently and long-lasting exposed to UVA radiation, this photosensitizing effect may contribute to initiation of deleterious photooxidative processes in tissue.

  UVA辐射在人类组织的不良反应中发挥着重要作用。UVA能够穿透皮肤的表皮和真皮，被各种生物分子吸收，特别是内源性光敏剂。这可能会产生有害的单重态氧（1O2），其会氧化细胞膜、脂蛋白和其他含脂结构（如表皮屏障）中的脂肪酸。有迹象表明，脂肪酸不仅是1O2的靶点，而且在已被氧化的情况下，还可以在UVA照射下充当潜在的光敏剂。在乙醇溶液中，五种不同的脂肪酸（硬脂酸、油酸、亚油酸、亚麻酸和花生酸）暴露于UVA辐射（355 nm，100 mW）下30秒。采用时间分辨法在1270 nm处检测到1O2的发光，并在光谱分辨实验中得到了确认。脂肪酸的双键数量越多，检测到的1O2光子就越多。此外，脂肪酸还在宽谱UVA下持续暴露长达240分钟。在此时间段内，UVA的吸收和1O2发光随着照射时间的增加显著上升，达到最大值后又下降。HPLC-MS分析显示，过氧化脂肪酸的量和1O2的生成在增加和减少的过程中是并行的。这表明过氧化脂肪酸在UVA照射下产生1O2的潜力很高。总之，脂肪酸及其过氧化产物作为弱的内源性光敏剂，但在持续的UVA照射下会成为强光敏剂。由于脂肪酸及其氧化产物在活细胞和皮肤中普遍存在，而皮肤往往会长时间暴露于UVA辐射中，这种光敏化效应可能会促成组织中有害光氧化过程的启动。
• [EN] BACTERIA ENGINEERED FOR CONVERSION OF ETHYLENE TO N-BUTANOL<br/>[FR] BACTÉRIES GÉNÉTIQUEMENT MODIFIÉES POUR LA CONVERSION D'ÉTHYLÈNE EN N-BUTANOL
  申请人：UNIV CALIFORNIA

  公开号：WO2015191611A1

  公开（公告）日：2015-12-17

  The present disclosure provides recombinant bacteria with elevated production of ethanol and/or n-butanol from ethylene. Methods for the production of the recombinant bacteria, as well as for use thereof for production of ethanol and/or n-butanol are also provided.

  本公开提供了具有从乙烯中产生乙醇和/或正丁醇产量升高的重组细菌。还提供了用于生产这些重组细菌以及用于生产乙醇和/或正丁醇的方法。
• [EN] LIQUID ORAL DOSAGE FORMULATIONS OF METHYLNALTREXONE<br/>[FR] FORMULATIONS POSOLOGIQUES ORALES LIQUIDES DE MÉTHYLNALTREXONE
  申请人：BAUSCH HEALTH IRELAND LTD

  公开号：WO2020225395A1

  公开（公告）日：2020-11-12

  Provided herein are pharmaceutical compositions comprising methylnaltrexone, lauryl sulfate or docusate, and at least one of an oil, a surfactant or a cosolvent, wherein the methylnaltrexone and lauryl sulfate or docusate are present as an ion pair. The pharmaceutical compositions may further comprise a surfactant so as to provide self-emulsifying methylnaltrexone delivery systems.

  本文提供了含有甲基纳曲酮、月桂酸十二烷基酯或多可酸盐，以及至少一种油、表面活性剂或共溶剂的制药组合物，其中甲基纳曲酮和月桂酸十二烷基酯或多可酸盐以离子对的形式存在。这些制药组合物还可能包含表面活性剂，从而提供自乳化的甲基纳曲酮传递系统。